Herbert Tilg

List of Publications by Year in Descending Order

129 papers	15,024 citations	51 h-index	122 g-index
147 ext. papers	19,525 ext. citations	11.8 avg, IF	7.41 L-index

#	Paper	IF	Citations
129	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. *Gut*, **2022**, 71, 156-162	19.2	56
128	PUFA-induced metabolic enteritis as a fuel for Crohn's disease.. *Gastroenterology*, **2022**,	13.3	1
127	Gut microbiome and health: mechanistic insights.. *Gut*, **2022**,	19.2	39
126	Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. *Bone*, **2022**, 154, 116202	4.7	4
125	Liver microbes controlling immunity: Facts and pitfalls.. *Cell Metabolism*, **2022**, 34, 510-512	24.6	0
124	Global multi-stakeholder endorsement of the MAFLD definition.. *The Lancet Gastroenterology and Hepatology*, **2022**,	18.8	18
123	Post-acute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases.. *Gastroenterology*, **2022**,	13.3	12
122	Uterine microbiota plasticity during the menstrual cycle: Differences between healthy controls and patients with recurrent miscarriage or implantation failure.. *Journal of Reproductive Immunology*, **2022**, 151, 103634	4.2	1
121	XIAP restrains TNF-driven intestinal inflammation and dysbiosis by promoting innate immune responses of Paneth and dendritic cells. *Science Immunology*, **2021**, 6, eabf7235	28	3
120	Reassessment of Relevance and Predictive Value of Parameters Indicating Early Graft Dysfunction in Liver Transplantation: AST Is a Weak, but Bilirubin and INR Strong Predictors of Mortality. *Frontiers in Surgery*, **2021**, 8, 693288	2.3	1
119	Modulation of Liver Inflammation and Fibrosis by Interleukin-37. *Frontiers in Immunology*, **2021**, 12, 603649	8.4	2
118	Auto-aggressive CXCR6 CD8 T cells cause liver immune pathology in NASH. *Nature*, **2021**, 592, 444-449	50.4	56
117	Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. *Gut*, **2021**,	19.2	19
116	Dietary spermidine improves cognitive function. *Cell Reports*, **2021**, 35, 108985	10.6	25
115	SARS-CoV-2 vaccines and donor recruitment for FMT. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 264-266	18.8	3
114	Calprotectin: from biomarker to biological function. *Gut*, **2021**, 70, 1978-1988	19.2	24
113	MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes. *Hepatology*, **2021**, 74, 2424-2435	11.2	2

112	Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development. *Cancers*, **2021**, 13,	6.6	4
111	Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 578-588	18.8	37
110	Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study. *Journal of Crohn's and Colitis*, **2021**, 15, 43-54	1.5	12
109	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. *United European Gastroenterology Journal*, **2021**, 9, 229-247	5.3	19
108	Coronary atherosclerosis profile in patients with end-stage liver disease prior to liver transplantation due to alcoholic fatty liver: a coronary CTA study. *European Radiology*, **2021**, 31, 494-503	8	4
107	Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. *Hepatology*, **2021**, 73, 833-842	11.2	71
106	Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. *Gut*, **2021**, 70, 585-594	19.2	2
105	NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought. *Gut*, **2021**, 70, 1212-1213	19.2	8
104	Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. *British Journal of Clinical Pharmacology*, **2021**, 87, 2256-2273	3.8	21
103	Gut microbiome, liver immunology, and liver diseases. *Cellular and Molecular Immunology*, **2021**, 18, 4-17	15.4	45
102	Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 972-978	4.5	1
101	Systemic inflammation as fuel for acute liver injury in COVID-19. *Digestive and Liver Disease*, **2021**, 53, 158-165	3.3	29
100	Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. *Gut*, **2021**, 70, 962-969	19.2	80
99	Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19. *Clinical and Translational Gastroenterology*, **2021**, 12, e00293	4.2	3
98	Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. *Lancet Respiratory Medicine,the*, **2021**, 9, 863-872	35.1	33
97	Using Infodemiology Metrics to Assess Public Interest in Liver Transplantation: Google Trends Analysis. *Journal of Medical Internet Research*, **2021**, 23, e21656	7.6	1
96	B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. *EBioMedicine*, **2021**, 70, 103539	8.8	16
95	Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 3464-3473	4.5	3

94	Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.. *Nature Metabolism*, **2021**, 3, 1596-1607	14.6	8
93	Decline in acute upper gastrointestinal bleeding during COVID-19 pandemic after initiation of lockdown in Austria. *Endoscopy*, **2020**, 52, 1036-1038	3.4	17
92	From NAFLD to MAFLD: when pathophysiology succeeds. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 387-388	24.2	73
91	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 430-432	18.8	82
90	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. *Gut*, **2020**, 69, 1555-1563	19.2	57
89	Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis?. *Gut*, **2020**, 69, 1373-1374	19.2	10
88	Prebiotic Effects of Partially Hydrolyzed Guar Gum on the Composition and Function of the Human Microbiota-Results from the PAGODA Trial. *Nutrients*, **2020**, 12,	6.7	12
87	Is There Decreasing Public Interest in Renal Transplantation? A Google Trends Analysis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
86	COVID-19 and the gastrointestinal tract: more than meets the eye. *Gut*, **2020**, 69, 973-974	19.2	113
85	Metabolic recovery after weight loss surgery is reflected in serum microRNAs. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	5
84	Gastric banding-associated weight loss diminishes hepatic Tsukushi expression. *Cytokine*, **2020**, 133, 155114	4	4
83	Intravenous iron supplementation therapy. *Molecular Aspects of Medicine*, **2020**, 75, 100862	16.7	20
82	Highly Elevated Plasma Glutamyltransferase Elevations: A Trait Caused by Glutamyltransferase 1 Transmembrane Mutations. *Hepatology*, **2020**, 71, 1124-1127	11.2	2
81	Cloak and dagger - secondary hemophygocytic lymphohistiocytosis caused by intravenous autoinfection. *American Journal of Hematology*, **2020**, 95, 330-332	7.1	1
80	Liver stiffness by transient elastography accompanies illness severity in COVID-19. *BMJ Open Gastroenterology*, **2020**, 7,	3.9	11
79	Live Confocal Imaging as a Novel Tool to Assess Liver Quality: Insights From a Murine Model. *Transplantation*, **2020**, 104, 2528-2537	1.8	4
78	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. *Metabolism: Clinical and Experimental*, **2020**, 113, 154413	12.7	16
77	The intestinal microbiota fuelling metabolic inflammation. *Nature Reviews Immunology*, **2020**, 20, 40-54	36.5	301

76	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. *Gut*, **2020**, 69, 1691-1705	19.2	118
75	Association of the COVID-19 pandemic with Internet Search Volumes: A Google Trends Analysis. *International Journal of Infectious Diseases*, **2020**, 95, 192-197	10.5	127
74	Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease. *Liver International*, **2020**, 40, 1610-1619	7.9	7
73	Faecal calprotectin indicates intestinal inflammation in COVID-19. *Gut*, **2020**, 69, 1543-1544	19.2	166
72	Dietary lipids fuel GPX4-restricted enteritis resembling Crohn's disease. *Nature Communications*, **2020**, 11, 1775	17.4	44
71	Pancreas-Microbiota Cross Talk in Health and Disease. *Annual Review of Nutrition*, **2019**, 39, 249-266	9.9	14
70	Gut Dysfunction and Non-alcoholic Fatty Liver Disease. *Frontiers in Endocrinology*, **2019**, 10, 611	5.7	45
69	Reply. *Liver Transplantation*, **2019**, 25, 344-345	4.5	
68	Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. *Liver International*, **2019**, 39, 758-769	7.9	43
67	Reply. *Liver Transplantation*, **2019**, 25, 1287-1288	4.5	
66	Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD. *Frontiers in Immunology*, **2019**, 10, 1070	8.4	20
65	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 781-793	18.8	29
64	Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease. *Nature Metabolism*, **2019**, 1, 1027-1029	14.6	8
63	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics: A Prospective Cohort Study. *Annals of Internal Medicine*, **2019**, 171, 695-702	8	50
62	Preoperative Assessment of Muscle Mass Using Computerized Tomography Scans to Predict Outcomes Following Orthotopic Liver Transplantation. *Transplantation*, **2019**, 103, 2506-2514	1.8	11
61	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. *Gut*, **2019**, 68, 2111-2121	19.2	169
60	Reply to Gostner and Fuchs. *American Journal of Clinical Nutrition*, **2019**, 109, 218-219	7	
59	Metabolomic analysis-Addressing NMR and LC-MS related problems in human feces sample preparation. *Clinica Chimica Acta*, **2019**, 489, 169-176	6.2	21

58	Heterozygosity for the alpha-1-antitrypsin Z allele in cirrhosis is associated with more advanced disease. *Liver Transplantation*, **2018**, 24, 744-751	4.5	42
57	The Intestinal Microbiota in Colorectal Cancer. *Cancer Cell*, **2018**, 33, 954-964	24.3	314
56	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 425-439	24.2	114
55	Adipose type I interferon signalling protects against metabolic dysfunction. *Gut*, **2018**, 67, 157-165	19.2	31
54	Recovery of ethanol-induced depletion ameliorates alcoholic liver disease. *Gut*, **2018**, 67, 891-901	19.2	258
53	Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030. *PLoS ONE*, **2018**, 13, e0200750	3.7	3
52	Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2685-2689	6.7	3
51	Weight Loss Induced by Bariatric Surgery Restricts Hepatic Expression. *Journal of Obesity*, **2018**, 2018, 7108075	3.7	5
50	Higher spermidine intake is linked to lower mortality: a prospective population-based study. *American Journal of Clinical Nutrition*, **2018**, 108, 371-380	7	101
49	European consensus conference on faecal microbiota transplantation in clinical practice. *Gut*, **2017**, 66, 569-580	19.2	520
48	Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes. *Diabetes*, **2017**, 66, 347-357	0.9	141
47	Prescription of oral antidiabetic drugs in Tyrol - Data from the Tyrol diabetes registry 2012-2015. *Wiener Klinische Wochenschrift*, **2017**, 129, 46-51	2.3	5
46	Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2974-2984	5.6	18
45	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. *Gut*, **2017**, 66, 1138-1153	19.2	508
44	A guiding map for inflammation. *Nature Immunology*, **2017**, 18, 826-831	19.1	284
43	Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression. *Liver International*, **2017**, 37, 299-306	7.9	8
42	NAFLD and diabetes mellitus. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 32-42	24.2	434
41	Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Hepatology*, **2016**, 64, 955-65	11.2	172

40	Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease. *Journal of Hepatology*, **2016**, 64, 872-80	13.4	57
39	Nonalcoholic fatty liver disease and hepatocellular carcinoma. *Metabolism: Clinical and Experimental* , **2016**, 65, 1151-60	12.7	98
38	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2016**, 10, 239-54	1.5	354
37	Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. *PLoS ONE*, **2016**, 11, e0167146	3.7	58
36	Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. *Liver International*, **2016**, 36, 688-95	7.9	24
35	Gut microbiome and liver diseases. *Gut*, **2016**, 65, 2035-2044	19.2	252
34	Treatment With α1-Antitrypsin for Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease: A Report of 2 Cases. *Transplantation*, **2016**, 100, e158-e159	1.8	1
33	Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). *Wiener Klinische Wochenschrift*, **2016**, 128, 679-690	2.3	26
32	Food, immunity, and the microbiome. *Gastroenterology*, **2015**, 148, 1107-19	13.3	193
31	Lipocalin-2 ensures host defense against Salmonella Typhimurium by controlling macrophage iron homeostasis and immune response. *European Journal of Immunology*, **2015**, 45, 3073-86	6.1	40
30	Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration. *Gut*, **2014**, 63, 1921-31	19.2	68
29	IL-37 protects against obesity-induced inflammation and insulin resistance. *Nature Communications*, **2014**, 5, 4711	17.4	143
28	Mechanisms behind the link between obesity and gastrointestinal cancers. *Baillière's Best Practice and Research in Clinical Gastroenterology*, **2014**, 28, 599-610	2.5	50
27	Intestinal permeability--a new target for disease prevention and therapy. *BMC Gastroenterology*, **2014**, 14, 189	3	810
26	Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. *Journal of Hepatology*, **2013**, 59, 1315-22	13.4	78
25	Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. *Nature Medicine*, **2013**, 19, 358-63	50.5	169
24	Too much fat for the gut's microbiota. *Gut*, **2012**, 61, 474-5	19.2	6
23	Diet and intestinal immunity. *New England Journal of Medicine*, **2012**, 366, 181-3	59.2	30

22	Pathways of liver injury in alcoholic liver disease. *Journal of Hepatology*, **2011**, 55, 1159-61	13.4	69
21	Gut microbiome, obesity, and metabolic dysfunction. *Journal of Clinical Investigation*, **2011**, 121, 2126-32	15.9	545
20	Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. *Molecular Medicine*, **2011**, 17, 840-5	6.2	121
19	NAFLD and extrahepatic cancers: have a look at the colon. *Gut*, **2011**, 60, 745-6	19.2	24
18	Relevance of TNF- gene polymorphisms in nonalcoholic fatty liver disease. *Expert Review of Gastroenterology and Hepatology*, **2011**, 5, 155-8	4.2	6
17	Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. *Gut*, **2010**, 59, 1259-64	19.2	173
16	Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2010**, 13, 391-6	3.8	24
15	Obesity, metabolic syndrome, and microbiota: multiple interactions. *Journal of Clinical Gastroenterology*, **2010**, 44 Suppl 1, S16-8	3	85
14	Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology*, **2010**, 52, 1836-46	11.2	1423
13	Vedolizumab, a humanized mAb against the 47 integrin for the potential treatment of ulcerative colitis and Crohn's disease. *Current Opinion in Investigational Drugs*, **2010**, 11, 1295-304		21
12	Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. *Journal of Hepatology*, **2009**, 51, 765-77	13.4	113
11	Obesity and the microbiota. *Gastroenterology*, **2009**, 136, 1476-83	13.3	148
10	Insulin resistance, inflammation, and non-alcoholic fatty liver disease. *Trends in Endocrinology and Metabolism*, **2008**, 19, 371-9	8.8	334
9	Inflammatory mechanisms in the regulation of insulin resistance. *Molecular Medicine*, **2008**, 14, 222-31	6.2	515
8	Short bowel syndrome: searching for the proper diet. *European Journal of Gastroenterology and Hepatology*, **2008**, 20, 1061-3	2.2	9
7	Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. *Clinical Science*, **2008**, 114, 275-88	6.5	176
6	Management strategies in alcoholic liver disease. *Nature Reviews Gastroenterology & Hepatology*, **2007**, 4, 24-34		119
5	Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. *Gastroenterology*, **2006**, 131, 934-45	13.3	274

4	How to modulate inflammatory cytokines in liver diseases. *Liver International*, **2006**, 26, 1029-39	7.9	90
3	Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nature Reviews Immunology*, **2006**, 6, 772-83	36.5	2193
2	Maintenance of Telomere Length in Peripheral Blood CD4+CD25+ Regulatory T-Cells of Cancer Patients Despite Active Proliferation.. *Blood*, **2005**, 106, 3309-3309	2.2	
1	Cytokines in alcoholic and nonalcoholic steatohepatitis. *New England Journal of Medicine*, **2000**, 343, 1467-76	59.2	760